Mekinist (Trametinib) by Novartis Pharma

Mekinist (Trametinib) by Novartis Pharmaceuticals Corporation

Indications and Usage

Mekinist is a kinase inhibitor used for the treatment of various conditions:

• Melanoma with BRAF V600E or V600K mutations
• Unresectable or metastatic melanoma
• Metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation
• Locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation
• Unresectable or metastatic solid tumors with BRAF V600E mutation
• Low-grade glioma (LGG) with a BRAF V600E mutation

It is important to note that Mekinist is not indicated for the treatment of patients with colorectal cancer due to known intrinsic resistance to BRAF inhibition.

Dosage and Administration

The recommended dosage of Mekinist in adult patients is 2 mg orally once daily. For pediatric patients, the dosage is based on body weight. It should be taken at least 1 hour before or 2 hours after a meal. Patient selection should confirm the presence of BRAF V600E or V600K mutation in tumor specimens prior to initiation of treatment.

Recommended Dosage

The recommended duration of treatment varies based on the specific condition being treated. Dosage modifications for adverse reactions are also provided.

Administration

Mekinist tablets should not be crushed or broken. For oral solution, proper dosing and administration training is required for caregivers. The solution can be used for 35 days after reconstitution and should be stored below 25°C (77°F) and not frozen.

Dosage Modifications for Adverse Reactions

Dose reductions and modifications are provided for adverse reactions associated with Mekinist, including hemorrhage, venous thromboembolic events, cardiomyopathy, ocular toxicities, pulmonary issues, febrile reactions, skin toxicities, and other adverse reactions.

FAQ

What is Mekinist used for?

Mekinist is used for the treatment of unresectable or metastatic melanoma with specific mutations, metastatic NSCLC, locally advanced or metastatic ATC, unresectable or metastatic solid tumors, and low-grade glioma with certain genetic mutations.

How should Mekinist be taken?

Mekinist should be taken orally once daily at least 1 hour before or 2 hours after a meal. The dosage may vary based on the patient's age, weight, and the specific condition being treated.

Are there any potential side effects of Mekinist?

Yes, Mekinist may cause adverse reactions such as hemorrhage, venous thromboembolic events, cardiomyopathy, ocular toxicities, pulmonary issues, febrile reactions, skin toxicities, and other adverse reactions. Dose reductions and modifications are available for these reactions.

Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a healthcare professional before making any decisions about your health or medication.